You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Minimal residual disease (MRD)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

Using Mass Spectrometry Detecting Minimal Residual Disease in

Recruiting
  • Multiple Myeloma
    • Tianjin, China
      InsituteHBDH
    Sep 8, 2022

    Multiple Myeloma Trial in United States (Daratumumab, Lenalidomide, Bortezomib)

    Recruiting
    • Multiple Myeloma
    • Ann Arbor, Michigan
    • +3 more
    Jan 19, 2023

    Leukemia, Lymphoma Trial in Houston (Ofatumumab)

    Active, not recruiting
    • Leukemia
    • Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 9, 2022

    Non-invasive MRD Assessment in Multiple Myeloma

    Recruiting
    • Myeloma
    • MRD Assessment
    • New York, New York
      New York Presbyterian Hospital/Columbia University Irving Medica
    Nov 15, 2022

    Multiple Myeloma, Cancer, Hematologic Cancer Trial in Cork (Discontinuation of maintenance treatment)

    Not yet recruiting
    • Multiple Myeloma
    • +2 more
    • Discontinuation of maintenance treatment
    • Cork, Ireland
      Cork University Hospital
    May 10, 2023

    Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)

    Recruiting
    • Colon Cancer
    • Resected Stage
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 23, 2022

    AML, Adult, Minimal Residual Disease Trial (MRD assessment)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • MRD assessment
    • (no location specified)
    Oct 13, 2023

    High Risk CLL, Chronic Lymphocytic Leukemia Trial (VenObi+Ven or VenObi+VenZan)

    Not yet recruiting
    • High Risk CLL
    • Chronic Lymphocytic Leukemia
    • VenObi+Ven or VenObi+VenZan
    • (no location specified)
    Jul 26, 2022

    MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

    Not yet recruiting
    • Multiple Myeloma
    • Minimal Residual Disease
      • (no location specified)
      Nov 1, 2023

      Pediatric ALL, B Cell, Minimal Residual Disease Trial in Seoul (Blinatumomab for Injection)

      Recruiting
      • Pediatric ALL, B Cell
      • Minimal Residual Disease
      • Blinatumomab for Injection
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Feb 20, 2022

      Local Advanced Esophageal Carcinoma

      Recruiting
      • Esophageal Squamous Cell Carcinoma
        • Shanghai, Shanghai, China
          Fudan University Shanghai cancer center
        Jun 16, 2022

        T-cell Acute Lymphoblastic Leukemia Trial in Chicago (Daratumumab / Hyaluronidase Injection)

        Recruiting
        • T-cell Acute Lymphoblastic Leukemia
        • Daratumumab / Hyaluronidase Injection
        • Chicago, Illinois
          Northwestern
        Jun 17, 2022

        Rectal Cancer Patients Based on ctDNA-MRD Technology

        Recruiting
        • Rectal Adenocarcinoma
        • +3 more
        • MRD detection
        • Guangzhou, Guangdong, China
          WeiWei Xiao
        Jul 31, 2023

        Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia Trial in Aurora (CD19 Directed CAR T Cell)

        Not yet recruiting
        • Acute Lymphoid Leukemia
        • Acute Lymphoblastic Leukemia
        • CD19 Directed CAR T Cell
        • Aurora, Colorado
          University of Colorado Hospital
        Sep 12, 2022

        Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

        Not yet recruiting
        • Multiple Myeloma
        • (no location specified)
        Jan 10, 2023

        Amyloidosis Trial in Boston (blood collection, bone marrow collection)

        Completed
        • Amyloidosis
        • blood collection
        • bone marrow collection
        • Boston, Massachusetts
          Boston Medical Center
        Sep 8, 2021

        MRD Detection by NGS in Pediatric B-ALL

        Completed
        • Acute Lymphoblastic Leukemia, Pediatric, Next Generation Sequencing
        • MRD
        • Hangzhou, Zhejiang, China
          The Children's Hospital of Zhejiang University School of Medicin
        Jul 25, 2023

        Minimal Residual Disease(MRD)in Pediatric B-acute Lymphoblastic

        Recruiting
        • B Acute Lymphoblastic Leukemia
        • Minimal residual disease (MRD) monitoring
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Center
        Jul 25, 2021

        ALL, Recurrent, Adult Trial in Germany (Blinatumomab)

        Active, not recruiting
        • ALL, Recurrent, Adult
        • Frankfurt (Main), Hessen, Germany
        • +21 more
        Mar 16, 2022

        Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

        Not yet recruiting
        • Minimal Residual Disease
        • Esophageal Squamous Cell Carcinoma
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Jun 10, 2023

          AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

          Not yet recruiting
          • AML, Adult
          • Minimal Residual Disease
          • chidamide and azacitidine
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Sep 27, 2023

          B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease Trial in Vancouver, Halifax

          Terminated
          • B-cell Adult Acute Lymphoblastic Leukemia
          • +2 more
          • blinatumomab
          • Vancouver, British Columbia, Canada
          • +2 more
          Feb 3, 2022

          Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)

          Recruiting
          • Stage II-III Gastric Cancer
          • MRD-guided therapy
          • Jinan, Shandong, China
          • +4 more
          Nov 27, 2023

          Cervical Cancer Trial in Suzhou (Chemoradiotherapy + Adjuvant chemo and Zimberelimab, Chemoradiotherapy (small pelvic) +

          Recruiting
          • Cervical Cancer
          • Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
          • Chemoradiotherapy (small pelvic) + Zimberelimab
          • Suzhou, Jiangsu, China
            The Affiliated Suzhou Hospital of Nanjing Medical University
          May 14, 2023